WELIREG Merck Sharp & Dohme (Australia) Pty Ltd
Product name
WELIREG
Accepted date
Apr-2024
Active ingredients
belzutifan
Proposed indication
For the treatment of renal cell carcinoma (RCC).
Application type
C (new indication)
Publication date
Apr-2024